Product Details - BRAVECTO®



For Miniature Dogs     (2 – 4,5 kg)
For Small Dogs           (> 4,5 – 10 kg)
For Medium Dogs       (> 10 – 20 kg)
For Large Dogs           (> 20 – 40 kg)
For Extra-Large Dogs (> 40 – 56 kg) 

Reg. No. G4083 (Act 36/1947)
Namibia Reg. No. V14/18.3.10/1259 NS0

This product may only be sold by persons registered in terms of section 23(1) (c) of the Veterinary and Para-Veterinary Professions Act, 1982 (Act No. 19 of 1982).

For the treatment and prevention of tick, flea and mite infestations in dogs. Bravecto® kills adult, as well as juvenile ticks (larvae and nymphs). Bravecto® can be used as part of a treatment strategy for Flea Allergy Dermatitis (FAD). For the treatment of Demodicosis caused by Demodex spp. and Sarcoptic mange mites. In a controlled trial, treatment with fluralaner resulted in the complete removal of Demodex spp. mites from treated dogs. For the treatment of Otodectes spp. mite infestations. 

Contains fluralaner equivalent to 25 to 56 mg/kg body weight.
Each chewable tablet contains:
Miniature Dogs:          112,5 mg
Small Dogs:                250 mg
Medium Dogs:            500 mg
Large Dogs:                1 000 mg
Extra-Large Dogs:      1 400 mg 


Store at or below 30 °C in a cool, dry place. 

Pharmacodynamic properties
Fluralaner is an acaricide and insecticide. It is efficacious against ticks (Ixodes spp., Dermacentor spp., Haemaphysalis elliptica and Rhipicephalus sanguineus) and fleas (Ctenocephalides spp.) and mites (Demodex spp., Sarcoptes spp., Otodectes spp.) on dogs. Fluralaner is systemically active on target parasites. Contact activity against ticks and fleas is of minor relevance. Fluralaner is a potent inhibitor of parts of the arthropod nervous system by acting antagonistically on ligand-gated chloride channels (GABA-receptor and glutamate-receptor). In a molecular on target study, fluralaner is not affected by dieldrin resistance.
In vitro, fluralaner overcomes resistance against amidines, organophosphates, cyclodienes, macrocyclic lactones, phenylpyrazoles, benzophenyl ureas, pyrethroids and carbamates.
In vivo, fluralaner is highly effective against fleas proven to be less susceptible to phenylpyrazole insecticides.

Pharmacokinetic properties
Following oral administration, fluralaner is readily absorbed reaching maximum plasma concentrations within 1 day. Food enhances the absorption. Fluralaner is systemically distributed and reaches the highest concentrations in the visceral fat, followed by liver, kidney and muscle. The prolonged persistence and slow elimination from plasma (t½ = 12 days) and the lack of extensive metabolism provide effective concentrations of fluralaner for the duration of the inter-dosing interval, ensuring efficacy for 12 weeks. The major route of elimination is the excretion of unchanged fluralaner in faeces (~ 90 % of the dose). Renal clearance is the minor route of elimination.


  • Use with caution in dogs with pre-existing epilepsy.
  • Safety in puppies less than 8 weeks of age and/or dogs weighing less than 2 kg has not been established.
  • Keep the product in the original packaging until use.
  • Do not use in case of hypersensitivity to fluralaner or to any of the excipients.
  • Can be used in breeding, pregnant and lactating dogs.
  • Bravecto® is well tolerated in MDR1 dogs following oral administration.
  • Although this remedy has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.


  • Do not eat, drink or smoke while handling the product.
  • Wash hands thoroughly with soap and water immediately after use of the product.
  • Do not store with food, drinks, medication or household products.
  • Do not administer at intervals shorter than 8 weeks as the safety for shorter intervals has not been tested.

Commonly observed adverse reactions in clinical trials (1,6 % of treated dogs) were mild and transient gastrointestinal effects such as diarrhoea, vomiting, inappetence, and drooling.

 Convulsions and lethargy have been reported very rarely in spontaneous (pharmacovigilance) reports.

The frequency of adverse reactions is defined using the following convention: 

  • very common (more than 1 in 10 animals displaying adverse reaction(s) during the course     of one treatment) 
  • common (more than 1 but less than 10 animals in 100 animals) 
  • uncommon (more than 1 but less than 10 animals in 1 000 animals) 
  • rare (more than 1 but less than 10 animals in 10 000 animals) 
  • very rare (less than 1 animal in 10 000 animals, including isolated reports). 


  • Administer tablets at or around the time of feeding for maximum effectiveness.
  • It can be mixed with food or given by hand since it is very palatable.
  • For optimal control of tick and flea infestation, Bravecto® should be administered at a 12 week interval.
  • Bravecto® can be administered all year round.
  • The chew tablets should not be broken or divided.


Weight (kg)

Tablet size

    2,0 - 4,5

112,5 mg for miniature dogs

> 4,5 - 10

250 mg for small dogs

> 10 - 20

500 mg for medium dogs

> 20 - 40

1 000 mg for large dogs

> 40 - 56

1 400 mg for extra-large dogs

Within each weight range a whole tablet must be used.
For dogs weighing more than 56 kg, use a combination of 2 tablets that most closely matches the body weight. 

Bravecto® was well tolerated following oral administration to puppies aged between 8 and 9 weeks and weighing between 2,0 and 3,6 kg at doses of up to 56 mg, 168 mg and 280 mg fluralaner/kg body weight (equivalent to 1, 3 and 5 times the maximum expected clinical dose) on 3 occasions at 8-week intervals. No treatment-related adverse effects were observed.
There were no findings on reproductive performance and offspring viability when up to 168 mg/kg of fluralaner (equivalent to 3 times the maximum treatment dose) was administered orally to Beagle dogs.
Bravecto® was well tolerated in Collies with MDR1-/1 following a single dose at 3 times the recommended dose. 

Bravecto® was shown to be effective* against fleas and various tick species.
* Efficacy > 90 to 95 %

Bravecto® is indicated for the treatment of the following:
TICKS: (Ixodes ricinus, Ixodes hexagonus, Ixodus scapularis, Dermacentor reticulatus, Dermacentor variabilis, Haemaphysalis elliptica and Rhipicephalus sanguineus.)
Directly after treatment, at least 90 % of ticks on dogs are killed within 8 hours. During the whole treatment interval, at least 90 % of ticks on dogs are killed within 12 hours.

FLEAS: (Ctenocephalides felis)
Directly after treatment, at least 95 % of fleas are killed within 8 hours. During the whole treatment interval, at least 95 % of fleas on dogs are killed within 12 hours. 

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

Effect on immature stages
The product kills adult as well as juvenile ticks (larvae, nymphs). Newly emerged fleas on a dog are killed before viable eggs are produced. An in vitro study also demonstrated that very low concentrations of fluralaner stop the production of viable eggs by fleas.

Control of flea infestations and Flea Allergy Dermatitis (FAD)
The flea life cycle is broken due to the rapid onset action and long lasting efficacy against adult fleas on the animal and the absence of viable egg production. Bravecto® effectively controls environmental flea populations in areas to which the dog has access. Bravecto® can be used as part of a treatment strategy for flea allergy dermatitis (FAD). 

A single oral administration of Bravecto® chewable tablets to dogs with Sarcoptes spp., Otodectes spp. infestations showed a 100 % reduction in live mite counts as well as a complete elimination of live mites 28 days after treatment administration. The treatment resulted in a reduction of skin lesions and increase of hair regrowth.
Single oral administration of Bravecto® chewable tablets is highly effective against generalised demodicosis caused by Demodex spp., with no mites detectable at 56 and 84 days following treatment. 

Light to dark brown chewable tablet with a smooth or slightly rough surface and circular shape. Some marbling, speckles or both may be visible.

Packaged in an aluminium foil blister with aluminium foil lid stock in an outer carton.

Intervet South Africa (Pty) Ltd.
20 Spartan Road, Spartan
1619, RSA
Tel: +27 (0) 11 923 9300
Fax: +27 (0) 11 392 3158 

Intervet GmbH
Siemensstrasse 107
1210 Vienna

16 April 2018